Until now, interventional radiologists and oncologists had no means to be certain that when embolic beads were placed into blood vessels at the precise, intended location or that they remained there over time. Now, partners BTG and Royal Philips have treated the first liver cancer patient with their recently approved LC Bead Lumi that is visible via imaging and can be used during an embolization procedure as well as afterward to monitor that the embolic beads remain in their intended location.
Advanced liver cancer is one of the toughest targets in biotech. But investigators at UT Southwestern say that a dendrimer nanoparticle used to carry microRNA directly to tumor cells has the potential to target the cancer and suppress tumors while sparing surrounding tissue.
Cardiovascular-focused Boston Scientific is moving deeper into oncology and expanding its vascular offerings with the purchase of the interventional radiology portfolio of CeloNova BioSciences. The deal with the San Antonio, TX-based startup involves a $70 million upfront payment with additional, undisclosed regulatory and sales milestones.
The clinical evaluation of cirrhosis can rely upon a whole range of standard medical tests including hepatic venous pressure gradient (HVPG), liver biopsy results, and liver stiffness testing. But Israeli med tech Exalenz Bioscience is working to develop a breath test for its BreathID system that could offer accurate diagnosis and monitoring for a version of the disease, NASH cirrhosis in a Phase II clinical trial with biotech micro-cap Galectin Therapeutics.
Colorado-based startup Surefire Medical has raised $11 million to help market its microcatheter-based infusion system to deliver embolic agents to liver cancer. The Surefire Infusion System was cleared by the FDA in 2011, but it's in ongoing testing by external investigators to see how it compares to a standard end-hole microcatheter.
Bayer and Onyx Pharmaceuticals' Nexavar has seen a lot of success as a liver cancer treatment, but as an adjuvant therapy for liver cancer, it could be awhile--if ever. On Tuesday, the drug missed its target in a Phase III trial, failing to meet the study's main goal of improving recurrence-free survival.
Researchers in China published an article in the journal Biomedical Materials demonstrating the drug-delivery potential of new gold nanoshells for cancer that also use hyperthermic effects to bring toxic cancer drugs to tumors with fewer side effects.
Queensbury, NY-based Delcath plans to fire 20% of its U.S. workforce to conserve cash and concentrate resources in Europe, where the company has CE mark clearance for its drug-device combo.
Germany's federal healthcare reimbursement program approved Delcath Systems' Chemosat with a Value 4 status.
Celsion was the center of a considerable amount of market buzz over the last year as the small biotech pushed a late-stage cancer drug through a Phase III liver cancer study. Its stock price tripled as investors rode a swell of enthusiasm that Celsion could beat the tough odds that face any small-cap company trying to make it all the way through an oncology program.